EU-GMP Adjustments in the next Years
Recommendation

27/28 May 2026
Batch Manufacturing Documents: from Preparation to Operational Excellence
EMA has published a three-year plan. This plan of the GMDP Inspectors Working Group (IWG) focuses on a network and regulatory science strategy, taking into account supply chain integrity and resilience, product quality and the impact of new manufacturing technologies on the supply chain. The work plan includes specific activities to achieve an objective as well as routine activities that contribute to the overall strategic objective. A large part of the IWG's work plan is derived from the Nitrosamines Lessons Learnt Exercise (LLE).
The plan also includes plans to revise the EU GMP guidelines
Chapter 1 (Pharmaceutical Quality System)
Submission of a final text for the revised chapter to the European Commission to encourage industry to adopt risk-based approaches to prevent shortages, taking into account initiatives such as the HMA-EMA Taskforce and industry inter-association guidance.
Chapter 4 (Documentation) and Annex 11 (Computerised Systems).
Submit the final texts for the amended Chapter and Annex to the European Commission to ensure data integrity in the context of GMP.
Annex 4 (Manufacture of Veterinary Medicinal Products other than Immunological Veterinary Medicinal Products)
Review comments received during stakeholder consultation on the concept paper and draft updated text. Submission of a final text to the European Commission.
Annex 15 (Qualification and Validation)
Review the Annex with regard to new technologies in installations, products and processes and consider whether updates are required.
Based on the LLE recommendations, consider whether the scope can be extended to APIs.
Annex 16 (Certification by a Qualified Person and Batch Release)
Following the LLE recommendations, consider revising the Annex to provide additional guidance on batch traceability.
GMP and Marketing Authorisation Holders
Revise the paper in line with the LLE recommendations to provide guidance to MAHs regarding appropriate quality agreement with manufacturers.
For further information, please see the EMA's "3-year work plan for the Quality domain".
Related GMP News
15.04.2026ICH Q9 Training Package updated
01.04.2026New EMA GMP Guidelines in the next three Years
01.04.2026New EMA Guidance: Risk Management for Elemental Impurities in Veterinary Medicinal Products
18.03.2026Sampling in the Focus of the FDA
11.03.2026EU Pharma Package: Final Texts officially published
11.03.2026FDA Guidance Plans for 2026


